Product Name
VMA21, siRNA
Full Product Name
VMA21 siRNA (Human)
Product Synonym Names
MEAX; XMEA; Vacuolar ATPase assembly integral membrane protein VMA21; Myopathy with excessive autophagy protein
Product Gene Name
VMA21 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q3ZAQ7
Specificity
VMA21 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human VMA21 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of VMA21 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
VMA21 sirna
siRNA to inhibit VMA21 expression using RNA interference
Applications Tested/Suitable for VMA21 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for VMA21. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001017980.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001017980.3
[Other Products]
UniProt Primary Accession #
Q3ZAQ7
[Other Products]
UniProt Secondary Accession #
A6NKV7; B3KUA9[Other Products]
UniProt Related Accession #
Q3ZAQ7[Other Products]
Molecular Weight
17,766 Da
NCBI Official Full Name
vacuolar ATPase assembly integral membrane protein VMA21
NCBI Official Synonym Full Names
VMA21 vacuolar H+-ATPase homolog (S. cerevisiae)
NCBI Official Symbol
VMA21 [Similar Products]
NCBI Official Synonym Symbols
MEAX; XMEA
[Similar Products]
NCBI Protein Information
vacuolar ATPase assembly integral membrane protein VMA21
UniProt Protein Name
Vacuolar ATPase assembly integral membrane protein VMA21
UniProt Synonym Protein Names
Myopathy with excessive autophagy protein
Protein Family
Vacuolar ATPase assembly integral membrane protein
UniProt Gene Name
VMA21 [Similar Products]
UniProt Entry Name
VMA21_HUMAN
NCBI Summary for VMA21
This gene encodes a chaperone for assembly of lysosomal vacuolar ATPase.[provided by RefSeq, Jul 2012]
UniProt Comments for VMA21
VMA21: Required for the assembly of the V0 complex of the vacuolar ATPase (V-ATPase) in the endoplasmic reticulum. Defects in VMA21 are the cause of X-linked myopathy with excessive autophagy (MEAX). MEAX is a childhood-onset disease characterized by progressive vacuolation and atrophy of skeletal muscle. It is inherited in recessive fashion, affecting boys and sparing carrier females. Onset is in childhood, and patients exhibit weakness of the proximal muscles of the lower extremities, progressing slowly to involve other skeletal muscle groups over time. Other organs including the heart and brain are clinically unaffected. Phenotype is due to an increase of lysosomal pH from 4.7 to 5.2, which reduces lysosomal degradative ability and blocks autophagy. This reduces cellular free amino acids, which up-regulates the mTOR pathway and mTOR-dependent macroautophagy, resulting in proliferation of large and ineffective autolysosomes that engulf sections of cytoplasm, merge together, and vacuolate the cell. Belongs to the VMA21 family. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Membrane protein, integral; Membrane protein, multi-pass
Chromosomal Location of Human Ortholog: Xq28
Cellular Component: endoplasmic reticulum membrane; ER-Golgi intermediate compartment membrane; COPII vesicle coat; lysosome; integral to membrane
Disease: Myopathy, X-linked, With Excessive Autophagy
Research Articles on VMA21
1. A Japanese family afflicted by X-linked myopathy with excessive autophagy displayed high urinary beta2 microglobulin without renal dysfunction. Decreased urine acidification in the distal convoluted tubules might be caused by the VMA21 gene mutation.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
